• LAST PRICE
    65.5100
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-0.0458%)
  • Bid / Lots
    64.0000/ 1
  • Ask / Lots
    68.8100/ 7
  • Open / Previous Close
    66.0100 / 65.5400
  • Day Range
    Low 64.8200
    High 66.4700
  • 52 Week Range
    Low 53.7900
    High 94.8600
  • Volume
    2,020,886
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Yesterday

      Show headlines and story abstract
    • 9:15AM ET on Thursday May 30, 2024 by Dow Jones
      Companies Mentioned: BRKR

      Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024
      -- The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics -- P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research -- P2 Plasma Enrichment is available as a CRO service via Biognosys' TrueDiscovery(R) platform, or as an in-house method for high-performance mass spectrometry end-users via licensing -- With the optional additional combination of TrueDiscovery(R) unbiased, deep mass spectrometry proteomics workflows with targeted Alamar NULISA affinity-based ultra-high sensitivity proteomics panels, Biognosys now enables the most quantitative and complete access to the human plasma proteome
    • 9:15AM ET on Thursday May 30, 2024 by Dow Jones
      Companies Mentioned: BRKR

      At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery(R) , TrueTarget(R) , and TrueSignature(R) research service platforms, our flagship software Spectronaut(R) , and the PQ500(TM) kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
    • 4:28AM ET on Thursday May 30, 2024 by MT Newswires
      Companies Mentioned: BRKR
      04:28 AM EDT, 05/30/2024 (MT Newswires) -- Bruker (BRKR) said Wednesday it priced a public offering of 6 million common shares. Underwriters have been granted a 30-day option to purchase up to an additional 900,000 shares. Net proceeds from the off...

Peers Headlines